Just this week, we learned about the tragic death of a 12-yearold child with congenital long QT syndrome (LQTS) after a physician unknowingly prescribed a medication that prolongs the QT interval and increases the risk of torsades de pointes (torsades), even when taken as directed. The young girl was evaluated in a health-system outpatient clinic and found to have bilateral otitis media and sinusitis. The clinic physician sent an electronic prescription to the health system's outpatient pharmacy for a ZITHRO-MAX (azithromycin) Z-PAK. This antibiotic has been associated with prolongation of the QT interval and may itself increase cardiovascular death, especially in patients with a high baseline risk of cardiovascular disease (www.ismp.org/sc?id=531). After taking the medication for 4 days, the child developed palpitations, dizziness, nausea, and transient fainting spells. The child was taken by ambulance to the health system's emergency department, where cardiac monitoring showed complete atrioventricular (AV) block associated with QT prolongation. The child quickly developed torsades, and her cardiac rhythm deteriorated to ventricular fibrillation. The young girl died despite all efforts to save her.
Avoid vitamin D products dosed and measured in drops.
Breastfeeding is the recommended method of feeding infants in order to provide them with the nutrients and immune factors needed in early life. However, breastfeeding alone does not provide the recommended dose of vitamin D, given low average levels of this vitamin in breast milk. Breastfed infants can synthesize additional vitamin D through routine sunlight exposure, but skin cancer concerns have led parents to protect infants from the sun with clothing, hats, and sunblock.
In 2008, the American Academy of Pediatrics (AAP) doubled the recommended daily dose of vitamin D for infants and children to 400 units a day. Parents may easily be confused given the various vitamin D products on the market with a wide variety of concentrations, such as 400 units in a single drop, 400 units per mL (e.g., ENFAMIL D-VI-SOL), 2,000 units per drop, and between 1,000 units to 10,000 units per mL.
continued on page 2-Drug-disease interaction > One choice too many... Time to eliminate teaspoonfuls I n an ambulatory pharmacy, a prescription was being refilled for cetirizine 1 mg/mL. When checking the medication, the pharmacist noticed that the directions read, "Take 2.5 mL (1.2 teaspoonfuls) by mouth once daily. " The pharmacist looked at the original prescription and corrected it to read, "Take 2.5 mL (1/2 teaspoonful) by mouth once daily. " The prescription had been filled previously with the incorrect directions. Fortunately, the mother had been giving her child the correct dose, measuring 2.5 mL for each dose and not using the incorrect teaspoonful designation. Typing a decimal point instead of a slash mark (1.2 instead of 1/2) can easily happen when tapping the wrong key on the keyboard because the keys are side-by-side. This longstanding problem wouldn't happen if teaspoonfuls were no longer used in dosing directions.
ISMP plans to publish a list of medication-related measures that can be used as part of a meaningful "dashboard" for senior leadership in healthcare organizations. You can help by taking a quick survey at: www.ismp.org/sc?id=512. We thank more than 100 practitioners who have already taken the survey, and we hope that many others will join in and provide us with input on how data is currently being used to identify and monitor safe medication use. The survey will remain open for a few more weeks. We really need your input! Creating Meaningful Measures for Medication Safety Figure 1 . Oral syringes obtained in April 2015 from 5 different large chain pharmacies and 2 independent pharmacies. All are potentially unsafe due to the risk of confusion between the mL and teaspoon scales.
continued on bottom of page 4-Eliminate teaspoonfuls > continued on page 2-SAFETY briefs > Drug-disease alerts disabled. To prevent alarm fatigue, the health system had turned off the drug-disease interaction alerts that were available in the prescriber order entry and ambulatory pharmacy computer systems. The health system's drug information vendor allowed the drug-disease interactions to be filtered according to severity level. The most restrictive level included medications that were contraindicated given specific disease states. When restricting the drug-disease alerts to those rated as contraindicated, the health system felt up to 90% of the alerts provided false positive or clinically insignificant results (e.g., lidocaine with EPINEPHrine and tachyarrhythmia; pseudoephedrine and COPD; propafenone and cardiac conduction disturbances).
Absence of system alerts. Even if the drug-disease interaction alerts had been turned on to display contraindicated interactions, the system still would not have alerted the physician and pharmacist to the lethal interaction. In the official azithromycin package insert, information about the interaction appears in the warnings and precautions sections, not under contraindications. The warning about prolongation of the QT interval and torsades suggests considering this risk in patients with certain cardiovascular conditions, including known QT prolongation. However, the health system's drug information database employed with the prescriber order entry system and pharmacy computer classified the importance of this interaction as not recommended, which was below the contraindicated and extreme caution severity levels. According to the health system, some other medications that prolong the QT interval (e.g., ondansetron) do not cause an alert at all at any severity level. The health system is following up with its EHR and drug information vendors to determine the cause, which could be related to how disease conditions are coded.
Unlinked comorbid condition.
Even if the drug-disease interaction alerts had been turned on and were functional for azithromycin and congenital LQTS in the ambulatory pharmacy system, the pharmacist would not have been alerted to the interaction. This is because the child's comorbid condition-congenital LQTS-was not documented in the ambulatory pharmacy computer system. The diagnosis had been listed in the child's EHR, but it was not linked to the pharmacy computer.
In this health system, physicians were required to provide an indication when ordering medications. In this case, the physician complied when prescribing azithromycin for the child (otitis media, sinusitis). Although prescriptions had been filled for the child previously at the ambulatory pharmacy, the child's congenital LQTS was not one of the diagnoses listed in the computer because the child had never taken a specific medication to treat this condition. The pharmacist did not have any reason to seek out additional diagnoses given that the physician had provided an appropriate indication for the azithromycin.
Overreliance on alerts.
Given an otherwise robust order entry alert system for allergies and drug-drug interactions, both the physician and pharmacist had come to rely on the computer alerts to warn them of any safety issues with the prescribed medications. They did not consider the fact that the systems would not necessarily alert them to drugdisease warnings and precautions identified in the prescribing information. From a human factors perspective, given that an alert was not issued, both practitioners believed there was no problem with the order.
SAFE PRACTICE RECOMMENDATIONS:
The health system where this event happened
is taking steps to ensure that an alert will be provided to both prescribers and pharmacists when a medication is contraindicated or not recommended for patients with a prolonged QT interval. To facilitate this process in your health system, consider the following recommendations.
> Drug-disease interaction-continued from page 1 continued on page 3-Drug-disease interaction > Recently, a 2-month-old infant was admitted to the hospital with generalized dystonia and cachexia, with prominent skin folds and loose skin reflective of a failure to thrive. The baby was found to have a total serum calcium level of 24.3 mg/dL and an ionized calcium level greater than 3.3 mmol/L, the highest value that could be measured by the laboratory used by the hospital. During the course of the investigation into the cause, it was discovered that the infant's mother had been giving her baby a vitamin D supplement in a concentration of 400 units per drop. The mother misinterpreted the instructions and gave one dropperful per day for weeks prior to the infant's hospitalization.
The product was Vitamin D3 Drops for Kids, manufactured by Natural Factors Canada. In addition to the very high concentration of vitamin D, the dropper included with the product could deliver an excessive amount of vitamin D, as happened here. This has been a factor in previous dosing errors and has been addressed as a potentially dang e r o u s practice by multiple org a n i z ations, including the US Food and Drug Administration (FDA) (www.ismp.org/sc? id=532). The concentrated drops are problematic if "drop" is confused with "dropperful," and/or if the prescriber specifies the dose by volume alone. This has happened in other cases, including one in which a mother bought a 2,000 units per drop instead of a 400 units per drop concentration and gave her child 1 mL doses as the doctor recommended instead of one drop (www.ismp.org/sc?id=533). It's also hard to be sure only 1 drop comes out of a dropper. Feeding tube connector changeover delayed again. The Global Enteral Device Supplier Association (GEDSA), the industry group that is overseeing the North American transition to a new connector standard for feeding tubes and associated equipment, has announced a delay in implementation of the new system because some manufacturers are not ready to distribute syringes with the new connectors. Syringes with ENFit tips are critical for the introduction of feeding tubes with the ENFit connectors and must be available to provide appropriate therapy for the tube-fed patient.
Since the changeover impacts the entire enteral feeding system across all healthcare settings, a careful and methodical transition to new, safer connectors is recommended over the course of 2015 and 2016. Administration sets with an ENFit connector and transition connector have already begun to arrive in hospitals this quarter. Unfortunately, the scheduled release for enteral-specific syringes with an ENFit tip and enteral feeding tubes with ENFit connectors is delayed until the first quarter of 2016. An article devoted to implementation of ENFit connectors appeared in our April 9, 2015 issue (www.ismp.org/sc ?id=534). More information on the transition is available at: www.ismp.org/sc?id=530.
Patches and suicide risk. A report describing improper disposal of a fentaNYL patch in the trash shed light on another issue with transdermal patches: patients on suicide precautions may remove medication patches or obtain them from disposal bins and ingest large doses of the medicacont'd from page 2 Evaluate your drug information database. Using a reliable resource, review the parameters of your drug information database and order entry systems to determine if an alert will appear when a drug that prolongs the QT interval and increases the risk of torsades is entered for a patient with a history of prolonged QT interval or torsades. CredibleMeds is one such resource (www.crediblemeds.org). The organization's website includes a free list of 175 medications that prolong the QT interval, which can be used to help evaluate the effectiveness of your order entry alert systems. The medications are grouped into one of four risk categories via a stratification process, which includes monitoring and analysis of scientific articles published in the literature, information in the official drug label, reports submitted to its website, and data from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
Build/modify severity of critical alerts. Work with your drug information vendor to build or modify the severity of alerts necessary to warn practitioners about possible serious or fatal adverse events in certain populations with drugs that prolong the QT interval. The health system where this error happened has downloaded a list of medications from CredibleMeds that should be avoided in patients with a prolonged QT interval, and has written the code necessary to ensure a clinically valid alert appears during order entry. CredibleMeds offers a free update service and will notify users whenever a drug is added, removed, or changed on the list. Although the time to build custom alerts varies depending on the technology in use, it took this health system about 20 hours to build the medication list and related diagnosis codes for the custom alerts.
Include comorbid conditions. Establish a system to gather and document all comorbid conditions in a structured diagnosis/problem list field in the patient's EHR, and to link this information to the prescriber and pharmacy order entry systems, to promote appropriate drug-disease interaction screening when new drugs are prescribed.
Avoid overreliance. While technology is often a pathway to improved patient outcomes, remind staff to avoid full reliance on any technology involved in the medication-use process. Also be sure prescribers and pharmacists know the types of alerts not available or turned off in the order entry systems. Keep in mind, the use of technology should be one part of an otherwise well integrated process that provides several levels of redundancy to ensure patient safety.
Reduce insignificant warnings.
Work to reduce the frequency of warnings that are not clinically significant to users. Frontline staff who repeatedly encounter clinical warnings can provide a wealth of information on this topic.
Once insignificant warnings have been reduced, organizations may want to display alerts related to contraindications (highest level alerts) and warnings and precautions (potentially lower level alerts) for pharmacists, but display only contraindications for physicians. Displaying different levels of alerts may be a strategy used for drug-disease interactions as well as drug-drug interactions and other drug safety issues. Assess other chronic conditions. As appropriate, expand this alert evaluation process to include other chronic conditions (e.g., myasthenia gravis, glaucoma, Parkinson's disease) for which certain medications should be avoided to prevent serious harm or death.
Patient/family education. While healthcare providers are ultimately responsible for each patient's safety when providing care, knowledgeable patients (and families) can provide an additional level of protection if they are active participants in their care and > Drug-disease interaction-continued from page 2 continued on page 4-Drug-disease interaction > > Drug-disease interaction--continued from page 3 > Eliminate teaspoonfuls-continued from page 1 tion by chewing the patch. Be sure suicide precautions include an assessment to determine if the patient is wearing a transdermal patch upon admission and to avoid their use in this population without carefully weighing the risks and benefits.
cont'd from page 3 have been educated about the importance of communicating comorbid conditions to all healthcare providers. They may also find it useful to carry a list of key medications that must be avoided based on existing comorbid conditions to share with healthcare providers.
Regulatory/pharmaceutical company/drug information vendor changes. ISMP encourages FDA to require label updates for drugs that should be contraindicated in patients with QT prolongation, replacing current warnings or precautions with a decisive contraindication when appropriate. Drug information vendors are encouraged to review the list of drugs that prolong the QT interval at CredibleMeds (which includes links to evidence in the literature) to determine whether the severity of any drug-disease interaction alert needs to be modified.
On a related note, ISMP encourages drug information vendors to evaluate their drugdrug interaction alert settings when more than one drug that prolongs the QT interval is prescribed (e.g., azithromycin and ondansetron), and to modify severity levels as necessary. Taking more than one drug with this adverse effect can lead to a similar tragic outcome.
ISMP Medical Director granted emeritus status. ISMP is pleased to announce that
Russell Jenkins, MD, the Institute's Medical Director for over 15 years, has been granted emeritus status and will retain the title, Medical Director Emeritus. Dr. Jenkins has been a long-time member of the ISMP Board of Trustees and will continue in that role as well as participate as needed as a member of the hospital consulting team. A recognized physician expert in hospital medication system safety and an outstanding teacher, his many contributions to our growing knowledge in patient safety and the ISMP mission have been extraordinary.
New ISMP Medical Director announced.
Ron Litman, DO, a pediatric anesthesiologist at The Children's Hospital of Philadelphia (CHOP) and Professor of Anesthesiology and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, has accepted the position of Medical Director at ISMP. Ron became a crusader for medication safety after investigating a fatal medication error in a child during anesthesia. He attended medical school at the NY College of Osteopathic Medicine, and completed a pediatric residency at Rainbow Babies and Children's Hospital in OH, an anesthesiology residency at Mount Sinai Medical Center in New York, and a fellowship in pediatric anesthesia and critical care at CHOP. We look forward to working with Ron in his new role.
If you would like to subscribe to this newsletter, visit: www.ismp.org/sc?id=382 ISMP Medication Safety Alert! Acute Care (ISSN 1550-6312) © 2015 Institute for Safe Medication Practices (ISMP). Subscribers are granted permission to redistribute the newsletter or reproduce its contents within their practice site or facility only. Other reproduction, including posting on a public-access website, is prohibited without written permission from ISMP. This is a peer reviewed publication. Perhaps the most important impetus for change can be seen in the 2015 certification criteria for health information technology (IT) systems published in the Federal Register by the Office of the National Coordinator for Health Information Technology (ONC). ONC is calling for IT systems to limit prescribers to use the metric system for all electronic medication orders (www.ismp.org/sc?id=542). That means electronically transmitted prescriptions from doctors' offices will be in mL only, enabling prescription directions to read the same way. So the time has finally come for lasting change. To prevent confusion, we hope all hospitals, ambulatory care, and community pharmacies are working toward (or have already accomplished) designating oral liquid doses metrically by only using mL in the patient directions. Patients will need an oral dosing device, such as an oral syringe or dosing cup that measures in mL only. Baxter, NeoMed, and BD have already stated they will be providing oral syringes with mL-only scales. The array of devices with combination markings in Figure 1 (page 1) should hopefully become a thing of the past.
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